Clinical Trial Update: Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

Navitoclax is being studied in a Phase 1 trial for relapsed or refractory high-risk myelodysplastic syndrome, with the study currently listed as ACTIVE_NOT_RECR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Navitoclax (navitoclax)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome | Phase 1 | Status: ACTIVE_NOT_RECRUITING